Home » Stocks » TCRX

TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) 1.09M
Net Income (ttm) -26.13M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

TScan Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

3 weeks ago - SEC

About TCRX

TScan Therapeutics is a preclinical-stage biopharmaceutical company focused on developing a robust pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our approach is based on the central premise that we can learn from patients who are winning their fight against cancer in order to treat those who are not. Using one of our proprietary platform technologies, TargetScan, we analyze the T cells of cancer patients with exceptional responses to immunotherapy to discover how the immune system ... [Read more...]

Industry
Biological Products
IPO Date
Pending
CEO
David Southwell
Employees
57
Stock Exchange
NASDAQ
Ticker Symbol
TCRX
Full Company Profile

Financial Performance

Financial Statements